Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTOR | P42345 | 11/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.51 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.48 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.44 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | PRKDC | P78527 | 1/20 | 0.44 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.43 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29590344 | 1.00 | MTOR (0.51) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 | |
| SCHEMBL29591439 | 0.94 | MTOR (0.51) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 | |
| SCHEMBL29590351 | 0.94 | KCNQ3 (0.46) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 | |
| SCHEMBL14782812 | 0.94 | KCNQ3 (0.46) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 | |
| SCHEMBL14783581 | 0.94 | MTOR (0.51) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 | |
| SCHEMBL14783011 | 0.94 | MTOR (0.52) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 | |
| SCHEMBL29591549 | 0.94 | MTOR (0.52) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 | |
| SCHEMBL29591622 | 0.93 | KCNQ3 (0.55) | KCNQ3KCNQ2HDAC3TP53MAPT | |
| SCHEMBL14783318 | 0.93 | KCNQ3 (0.55) | KCNQ3KCNQ2HDAC3TP53MAPT | |
| SCHEMBL15688579 | 0.93 | MTOR (0.51) | MTORPIK3CAPIK3CGKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | claimed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | claimed |
| US-10065932-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2018-09-04 | — | — | US | claimed |
| US-20180134669-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2018-05-17 | — | — | US | claimed |
| EP-2755657-B1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA INC (US) | 2017-11-29 | — | — | EP | claimed |
| US-9518029-B2 | Certain chemical entities, compositions, and methods | NEUPHARMA, INC. (US) | 2016-12-13 | — | — | US | claimed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | claimed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | claimed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | claimed |
| CN-115403531-A | Chemical entities, compositions, and methods as kinase inhibitors | 润新生物公司 | 2022-11-29 | — | — | CN | disclosed |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2022-08-11 | — | — | US | disclosed |
| CN-108794411-B | Certain chemical entities, compositions, and methods | 润新生物公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2021-02-11 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. | 2015-06-11 | — | — | US | disclosed |
| EP-2755657-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Neupharma, Inc. (US) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013040515-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2013-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10065932-B2 | Certain chemical entities, compositions, and methods | BRAF, NRAS, KRAS | MTOR 477/4885PIK3CA 38/4885PIK3CG 139/4885 |
| US-20180134669-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | MTOR 477/4885PIK3CA 38/4885PIK3CG 139/4885 |
| US-20150158826-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | MTOR 477/4885PIK3CA 38/4885PIK3CG 139/4885 |
| US-20210040048-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | MTOR 402/4885PIK3CA 34/4885PIK3CG 124/4885 |
| US-20220251049-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | BRAF, NRAS, KRAS | MTOR 402/4885PIK3CA 34/4885PIK3CG 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.